Resultados financieros en millones de dólares estadounidenses. El ejercicio fiscal es febrero - enero.
Breakdown
TTM
09/30/2022
09/30/2021
09/30/2020
09/30/2014
09/30/2013
Ingresos
0
0
0
0
0
0
Crecimiento de los Ingresos (YoY)
--
--
--
--
--
--
Costo de los ingresos
0
0
0
0
--
--
Utilidad bruta
0
0
0
0
--
--
Venta, General y Administración
0
0
0
0
0
0
Investigación y Desarrollo
--
--
--
--
--
--
Gastos de Operación
0
0
0
0
0
0
Otras Ingresos (Gastos) No Operativos
--
0
0
--
--
--
Ingreso antes de impuestos
0
0
0
0
0
0
Gasto por Impuesto a la Renta
0
--
--
0
0
0
Ingreso Neto
0
0
0
0
0
0
Crecimiento de la Utilidad Neta
--
--
--
--
--
--
Acciones en Circulación (Diluidas)
16.63
18.13
18.13
16.63
8.96
8.96
Cambio de Acciones (YoY)
--
0%
9%
--
0%
0%
EPS (Diluido)
0
0.02
0
0
0
0
Crecimiento de EPS
--
-4,800%
-86%
--
26%
-39%
Flujo de efectivo libre
0
0
0
0
0
0
Flujo de efectivo libre por acción
--
--
--
--
--
--
Margen bruto
0%
0%
0%
0%
--
--
Margen de operación
0%
0%
0%
0%
0%
0%
Margen de beneficio
0%
0%
0%
0%
0%
0%
Margen de flujo de caja libre
0%
0%
0%
0%
0%
0%
EBITDA
0
0
0
0
0
0
Margen de EBITDA
0%
0%
0%
0%
0%
0%
D&A para EBITDA
0
0
0
0
0
0
EBIT
0
0
0
0
0
0
Margen de EBIT
0%
0%
0%
0%
0%
0%
Tasa de Impuesto Efectiva
0%
--
--
0%
0%
0%
Estadísticas clave
Cierre Anterior
$0.02
Precio de apertura
$0.02
Rango del día
$0.02 - $0.02
Rango de 52 semanas
$0.0033 - $0.1
Volumen
100
Volumen promedio
1.2K
EPS (TTM)
-0.00
Rendimiento de dividendos
--
Cap. de mercado
$362.6K
¿Qué es CBDG?
THC Farmaceuticals, Inc. engages in the research and development of cannabis pharmaceutical products. The company is headquartered in Scottsdale, Arizona and currently employs 2 full-time employees. The company went IPO on 2012-08-22. The firm specializes in the discovery, development, and commercialization of novel cannabinoid-based products in dental, ophthalmology and other medical disciplines. The company offers the combination of its proprietary developments with its clinicians and scientists to unlock the therapeutic properties of cannabis and its bioactive compounds. The firm owns clinical research center and cannabidiol (CBD) manufacturing facility in California. Its business plan includes conducting cannabinoids research and development in collaboration with cannabis research centers worldwide with the goal of developing novel and advanced therapeutic methods for the treatment of common medical conditions with cannabis-based therapies and to conduct pre-clinical investigations and randomized, placebo-controlled trials of CBD-based compounds and develop condition-specific medications. The company offers a network of micro vending kiosk systems.